IL2 and cancer: Strong evidence indicates that IL‐2 is involved in mediating T cell proliferation, survival, and differentiation to promote antitumor immunity.[20, 21] Antagonists of major inflammatory cytokines can be used safely in patients with advanced‐stage cancer and may contribute to disease stabilization.[22] Our findings provide a blueprint of various cytokines in the tumor microenvironment based on 3‐HAA treatment, implying that 3‐HAA treatment combined with harnessing cytokines may be an optimal setting for cytokine‐based therapy.